This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

On November 14, MPM BioImpact disclosed in a Securities and Exchange Commission filing that it sold out its entire stake in MBX Biosciences (NASDAQ:MBX), reducing exposure by an estimated $14.8 million.According to a filing with the Securities and Exchange Commission dated November 14, MPM BioImpact sold its entire position in MBX Biosciences during the third quarter. The fund exited 1,294,416 shares, eliminating its exposure and reducing reportable U.S. equity holdings by an estimated $14.8 million based on quarterly average pricing.Top holdings after the filing:  Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool